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Abstract
Introduction: Anti-glycan antibodies are a promising tool for differential diagnosis and disease stratification of patients with
Crohn’s disease (CD). We longitudinally assessed level and status changes of anti-glycan antibodies over time in individual
CD patients as well as determinants of this phenomenon.
Methods: 859 serum samples derived from a cohort of 253 inflammatory bowel disease (IBD) patients (207 CD, 46 ulcerative
colitis (UC)) were tested for the presence of anti-laminarin (Anti-L), anti-chitin (Anti-C), anti-chitobioside (ACCA), anti-
laminaribioside (ALCA), anti-mannobioside (AMCA) and anti-Saccharomyces cerevisiae (gASCA) antibodies by ELISA. All
patients had at least two and up to eleven serum samples taken during the disease course.
Results: Median follow-up time for CD was 17.4 months (Interquartile range (IQR) 8.0, 31.6 months) and for UC 10.9 months
(IQR 4.9, 21.0 months). In a subgroup of CD subjects marked changes in the overall immune response (quartile sum score)
and levels of individual markers were observed over time. The marker status (positive versus negative) remained widely
stable. Neither clinical phenotype nor NOD2 genotype was associated with the observed fluctuations. In a longitudinal
analysis neither changes in disease activity nor CD behavior led to alterations in the levels of the glycan markers. The ability
of the panel to discriminate CD from UC or its association with CD phenotypes remained stable during follow-up. In the
serum of UC patients neither significant level nor status changes were observed.
Conclusions: While the levels of anti-glycan antibodies fluctuate in a subgroup of CD patients the antibody status is widely
stable over time.
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Introduction
The diagnosis of inflammatory bowel disease (IBD) and the
differentiation between ulcerative colitis (UC) and Crohn’s disease
(CD) is currently based on the combination of clinical, laboratory,
radiological, endoscopic and histopathologic criteria [1]. However,
in about 15% of colitis patients a definitive diagnosis cannot be
made, a disease category termed indeterminate colitis (IC). In
addition, CD is characterized by the frequent occurrence of
complicated disease behavior,defined asfistulaeorstenoses, and the
need for CD-related surgery in a high proportion of patients [2,3,4].
Serological markers linked to CD, such as anti-Saccharomyces
cerevisiae (ASCA), anti-Pseudomonas-associated sequence I2 (anti-I2),
outer membrane porin C (OmpC) of Escherichia coli antibodies and
antibodies against the bacterial flagellin cBir1 (Anti-cBir1) have
been extensively investigated for diagnosis and disease stratification
[5,6]. The most recently described serum markers directed against
microbial antigens are anti-glycan-antibodies. A panel of antibodies
consisting of anti-Saccharomyces cerevisiae antibodies (gASCA), anti-
mannobioside carbohydrate antibodies (AMCA), anti-laminaribio-
side carbohydrate antibodies (ALCA), anti-chitobioside carbohy-
drate antibodies (ACCA), anti-laminarin carbohydrate antibody
(Anti-L) and anti-chitin carbohydrate antibody (Anti-C) has been
reported in several independent cohorts to show a high discrimi-
natory capacity for CD versus UC and association with and
prediction of complicated CD behavior [7,8,9,10,11,12,13].
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number of prospective studies in patient cohorts examining the utility
of anti-glycan antibodies and other serum markers for diagnosis,
disease stratification and prediction [5,6,7,8,9,10,11,12,13,14,15]
strikingly limited information is available on stability of antibody
levels or antibody status (positive versus negative) over time. Most
existing investigations determine stability of markers by facilitating
one single sample per patient but this single-point cross-sectional
study design makes claims about stability and potential influencing
factors on level changes conflicting [7,9,16,17,18]. Whereas some
data are available about level and status changes of serum markers
over time in individual patients [11,14,19,20,21,22,23,24], all studies
suffer from low patient numbers and/or short follow-up times. No
publication exists assessing the stability of the novel anti-glycan
antibodies in individual patients over time.
In contrast to this lack of information, knowledge in this field is
crucial not only for interpreting existing studies but also for the
design of future prospective trials that can ultimately lead to
routine use of these biomarkers in clinical practice. The aim of this
study was to fill these information gaps by I) defining the extent of
level changes of anti-glycan antibodies in individual patients over
time, II) interrogating potential associations of clinical factors and
genotypes with marker fluctuations, III) performing a longitudinal
analysis following marker levels correlated with distinct clinical
events over time and IV) investigating, if the accuracy of the
marker panel to differentiate UC from CD and association with
complicated CD behavior changes over time.
Methods
Patient population
We performed a longitudinal cohort study among adult IBD
patients. All IBD in- and outpatients seen at our tertiary referral
center between 2000 and 2006 were considered for participation
in the study. The diagnosis of CD and UC was made based on
clinical, radiographic, endoscopic and histopathologic criteria
according to Stange et al. [1,25].
Inclusion criterion for this study was the presence of more than
one serum sample per individual IBD patient during the disease
course. The samples were collected at arbitrary visits to our
hospital. Clinical data including age at diagnosis, body mass index
(BMI), gender, date of sample procurement, date and type of first
complication and surgery, medication and disease location were
obtained or updated, respectively, for each single visit and time
point of sample procurement separately by the treating physician
of the IBD unit. Collected data were transferred and stored in a
secure coded anonymized database for analysis. In July 2007, all
patient charts and the database were reviewed and updated for the
data points mentioned above without knowledge of the antibody
values. The treating IBD physician determined CD activity based
on the criteria included in the Crohn’s disease activity index
(CDAI) at the time of the patient visit and patients were grouped
in active (CDAI.150) and non-active disease (CDAI,150),
without assigning a specific CDAI point value. This patient cohort
represents a subgroup of the previously reported cross-sectional
study [11].
Signed informed consent was obtained from all participants.
The ethics committee of the University of Regensburg approved
the study.
Serological analysis
After procurement of the blood samples the serum was
separated by centrifugation and kept frozen at 280uC until use.
All sera were analyzed at the same time for the levels of gASCA
IgG, ALCA IgG, ACCA IgA, AMCA IgG, Anti-L IgA and Anti-C
IgA in a blinded manner as previously described [11]. All assays
were performed by ELISA following the manufacturer’s condi-
tions (Glycominds, Ltd; Lod, Israel). The optical density is directly
proportional to the amount of bound antibody. Results were
expressed as ELISA units (EU), which is a value relative to a
calibration serum sample. The cut-off values were used as
previously determined in a larger cross sectional analysis using
ROC curves for 90% specificity of CD versus a large control
group consisting of UC, other inflammatory GI-diseases, non-GI
diseases and healthy controls [11]: ACCA 90 EU, Anti-L 120 EU,
Anti-C 50 EU, ALCA 60 EU, AMCA 100 EU, gASCA 50 EU.
For the level of immune response of the serum-antibodies and
for analysis of association with certain phenotypes quartile scores
for each serologic marker were calculated, as previously described
[7,9,11,19]. Briefly, for each antibody patients whose antibody
levels were in the first, second, third and fourth quartile of the
distribution were assigned a quartile score of 1, 2, 3 or 4,
respectively. By adding individual quartile scores for each glycan
antigen a semi-quantitative quartile sum score (QSS, range 6–24)
representing the cumulative quantitative immune response
towards all six antigens for each patient was obtained. In other
words the QSS semiquantitatively depicts the overall serologic
immune response taking into consideration the levels of all tested
antibodies per sample. The QSS at the time of first sample
procurement was used as a reference for the longitudinal follow-up
analysis.
CRP was recorded as positive (values.0.5 mg/l) or negative
(values,0.5 mg/l).
Determination of NOD2 genotypes of the IBD patients
Standardized TaqManH SNP Genotyping Assays (Applied
Biosystems, Foster City, USA) were used to determine the
genotype of the three main CD-associated NOD2 variants SNP
8, 12 and 13 (rs2066844, rs2066845 and rs5743293). All processed
data were written to and administered by a previously described
database-driven laboratory information management system
(LIMS) [26]. Duplicate or related samples were identified and
excluded from the analyses, using algorithms implemented in the
LIMS. All SNPs had a high call rate (.=90% in cases and
controls), were not monomorphic (minor allele frequency ,1% in
cases or controls), and did not deviate from Hardy-Weinberg
equilibrium (HWE) in the control sample (PHWE.0.001).
Phenotypical characteristics of IBD patients
The IBD physician assessed the IBD patients for disease
phenotype at arbitrary visits during the disease course. Patient
demographics at time of first sample procurement can be seen in
Table 1. For the purpose of this study complicated disease
behavior in CD patients was defined as the occurrence of fistulae
or stenoses before or during follow-up. We additionally distin-
guished internal penetrating from perianal fistulizing disease.
Furthermore, we examined the need for CD-related surgery
during the follow-up period. CD-related surgery included 23
patients that had surgeries other than bowel resection, 64 patients
that had bowel resection only and 67 that had both types of
surgeries during follow-up.
Statistical analysis
Descriptive statistics were computed for all variables. These
include means, standard deviations and percentiles for continuous
factors and frequencies for categorical variables. Lin’s concor-
dance correlation coefficients were estimated to assess correlation
between first and maximal change samples. Associations of level
Levels of Anti-Glycan Markers in Crohn’s Disease
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logistic regression models and adjustments for total follow-up time
were done. To study changes in antibody levels, linear mixed
models were built; time since diagnosis, use of immunosuppres-
sants, active disease, occurrence of complication, and IBD-related
surgery were included in the models. An unstructured covariance
Table 1. Cohort Characteristics.
Factor CD UC
(N=207) (N=46)
Female, n (%) 103 (49.8) 18 (39.1)
Mean age at 1st sample (years) (SD) 35.3 (12.1) 38.0 (12.5)
Mean BMI (kg/m
2) (SD) 23.6 (5.1) 24.3 (4.7)
Mean age at diagnosis (years) (SD) 28.6 (11.9) 33.1 (12.6)*
Median disease duration at time of first sample (months) (P25, P75) 52.7 (9.2, 122.9) 40.9 (12.9, 97.6)
Median follow-up after first sample (months) (P25, P75) 17.4 (8.0, 31.6) 10.9 (4.9, 21.0)*
Location
Ileum Involvement 178 (86.0) ----
Proctitis/Left Colon ---- 11 (24.4)
Subtotal/Pancolitis ---- 34 (75.6)
CRP.0.5 mg/l any time during FU{ 142 (69.3) 25 (54.4)
Behaviour (Montreal classification)T -
B1 40 (19.4) ---
B1p 20 (9.7) ---
B2 50 (24.3) ---
B2p 17 (8.3) ---
B3 48 (23.3) ---
B3p 31 (15.1) ---
IBD related surgery (%) 154 (74.4) ---
NOD2 Genotype{
R702W C.T
CC 1 (0.5) 0 (0.0)
CT 32 (17.0) 1 (2.3)
TT 155 (82.5) 42 (97.7)
G908R G.C
CC 1 (0.5) 0 (0.0)
GC 12 (6.1) 2 (4.6)
GG 184 (93.4) 42 (95.5)
L1007fsinsC -/C
C/C 7 (3.6) 0 (0.0)
-/C 43 (21.9) 3 (6.8)
-/- 146 (74.5) 41 (93.2)
All SNPs
wt 107 (56.9) 37 (86.1)*
mut 81 (43.1) 6 (13.9)
Number of serology tests per subject
2 76 (36.7) 29 (63.0)
3 56 (27.1) 6 (13.0)
4 26 (12.6) 5 (10.9)
$5 49 (23.7) 6 (13.0)
BMI, body mass index; IBD, inflammatory bowel disease; CD: Crohn’s disease; UC: Ulcerative colitis.
P25, P75: 25th and 75th percentiles; SD: standard deviation.
*p,0.05 versus other patient group.
{2 CD patients did not have any CRP measures during follow-up.
T -One patient did not have clinical information regarding the occurence of fistula.
{Complete NOD2 Genotype information was available for 188 CD and 43 UC patients.
doi:10.1371/journal.pone.0018172.t001
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repeated measures. The sensitivity, specificity, positive and
negative predictive values were estimated to assess whether the
validity of each marker in diagnosing CD changed with repeated
samples; subjects with at least 4 samples were included in this
analysis. In addition, this same group of patients was used to study
the association between antibody levels, positivity, number of
positive markers and quartile group with Crohn’s disease
complications; Wilcoxon rank sum tests and Pearson’s chi-square
tests were used, as appropriate. A p,0.05 was considered
statistically significant, unless otherwise stated. SAS version 9.2
software (The SAS Institute, Cary, NC) and R version 2.10.1 (The
R Foundation for Statistical Computing, Vienna, Austria) were
used for all analyses.
Results
20% of the sera were collected within six months, 30% within
one year of diagnosis. The frequency of testing for the individual
patients can be seen in Table 1. The median time between
sample procurements in the subjects was 6.2 months (Interquartile
range (IQR) 3.5 months–12.2 months).
I) Definition of level and status changes over time
As not all samples were taken at time of diagnosis and follow-up
times varied we first tested if these two criteria have an influence
on our analysis. The magnitude of level changes in our IBD cohort
was not dependent on the time from diagnosis to first sample
procurement. In addition, there was no significant time-level
association between subjects with a short or long follow-up period,
indicating that the observed level changes are independent of the
observation time (data not shown). This suggests that our cohort
can be used for an analysis of fluctuations over time, despite not all
samples being taken at the time of IBD diagnosis or with a fixed
follow-up time.
Level changes in Crohn’s disease. We next characterized
the level changes of the glycan markers in patients with CD. We
noted substantial changes of the overall immune response depicted
by the QSS and of levels of all tested single serum markers in a
subgroup of individual CD patients over time (Figure 1 showing
Figure 1. A. Changes in quartile sum score over time. Profile plots for changes in the quartile sum score (QSS) in individual Crohn’s disease (CD) and
Ulcerative colitis (UC) patients over time. The broken lines represent four equal sections of the QSS. The blue, green, yellow and red lines indicate
patients starting in a certain section of the QSS. Depicted is a random set of 50 subjects per graph. B. Maximal changes in the quartile sum score.
Scatter plots comparing the quartile sum score (QSS) of the first sample and the sample with the maximal changes in QSS during follow-up in Crohn’s
disease (CD) and Ulcerative colitis (UC) patients. The size of the dots represents the number of patients per datapoint. C. Maximal changes in number
of positive markers. Scatter plots comparing the number of positive markers of the first sample and the sample with the maximal changes in quartile
sum score during follow-up in Crohn’s disease (CD) and Ulcerative colitis (UC) patients. The size of the dots represents the number of patients per
datapoint. D. Stability in antibody status over time. First sample compared to sample with with the maximal changes in quartile sum score during
follow-up in Crohn’s disease (CD) and Ulcerative colitis (UC) patients. Values are presented as N (%) for changes in marker status. gASCA: anti-
Saccharomyces cerevisiae antibodies, ACCA: anti-chitobioside carbohydrate IgA antibodies, ALCA: anti-laminaribioside carbohydrate IgG antibodies,
AMCA: anti-mannobioside carbohydrate IgG antibodies, Anti-L: anti-laminarin carbohydrate antibody, Anti-C: anti-chitin carbohydrate antibody; pos.:
positive, neg.: negative; *Anti-L and Anti-C were not available in all patients.
doi:10.1371/journal.pone.0018172.g001
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markersinCDpatients).Todescribethemagnitudeoflevelchanges
in CD patients we first divided the QSS into four equal sections,
assigned the CD subjects to a respective section and identified
patients with changes of their QSS section over time (color coded in
Figure 1A). Between 47.1% and 79% of the CD patients per
section (versus 0% to 50% of the UC subjects; Figure 1A) changed
their QSS section at least once during follow-up.
We next categorized the average fluctuation per individual patient
by calculating the Z-scores (level changes in standard deviations
(SD) from the per-patient mean) for all patients and samples. When
taking into account the average Z-scores per patient, which includes
all observed marker changes, we found while the absolute changes
of the marker levels are more pronounced in CD versus UC the
relative changes are comparable, which is true for the QSS and the
levels of all single markers (Table S1).
To classify the maximal extent of level changes in individual CD
patients over time we identified the samples with the maximal
change in QSS (increase or decrease) compared to the first
available sample per individual CD patient during follow-up. In
other words we identified the two samples per individual patient
with the maximal changes in serologic immune response to the
tested glycan epitopes. The comparison of the first sample and the
sample with the maximal QSS changes during follow-up can be
seen in Figure 1B. We also assessed the maximal level changes for
each individual antibody (Table 2; Figure S2). This further
corroborated the finding of marked fluctuations in the overall
immune response in a subgroup of CD patients. In CD patients
the maximal Z-score per patient was 0.91 (SD 0.38) (versus UC
0.76 (SD 0.36)) again indicating that the relative level changes are
comparable between CD and UC.
Taken together we show that on average across the whole CD
cohort individual marker levels are rather stable, with however
certain patients exhibiting stronger average and maximal fluctua-
tions. The relative level changes are comparable in CD versus UC,
with stronger absolute changes in CD.
Status changes in Crohn’s disease. A differentwayto assess
stability in serologic markers is to use a dichotomic categorization -
positive or negative for a respective antibody or if investigating a
panel the number of positive markers. We therefore tested how often
the levelsof the single markerscross the respective cut-offvaluesover
time, changing their status from positive to negative or vice versa. In
CD subjects in a median of 3.3% of the visits (IQR 0.0–11.1;
minimum (min.) 0, maximum (max.) 50) any of the marker status
changed compared to the previous consultation (versus UC with a
median of 0% of the visits (IQR 0; min. 0, max. 16.7).
Consideringthe two samples perindividualpatient with the maximal
changes in immune response during follow-up we next characterized
the longitudinal CD patient samples for stability in marker status
(positive versus negative for a respective antibody). We found a
strikingly stable antibody status for both the total number of positive
markers over time (Figure 1C) as well as for each single antibody
(Figure 1D) per individual patient. Only between 7.3% (ASCA) and
18.3% (AMCA) of the CD patients changed the antibody status of an
individual marker either from positive to negative or from negative to
positive. This indicates while marked level changes occur in a
subgroup of CD patients the antibody status is largely stable.
Level and status changes in ulcerative colitis. As partly
stated aboveand incontrasttotheserum of CDpatientsthe absolute
changes in the overall immune response and in the antibody status
over time in UC patients were minute (T a b l e2 ;F i g u r e1 ;F i g u r e
S3). Only between 0% and 8.7% of the UC patients changed the
antibody status of an individual marker during follow-up.
II) Association of level or status changes with clinical
phenotypes
After defining the magnitude of level changes over time we
aimed to assess clinical and genetic factors that are associated with
Table 2. Changes in antibody levels: First sample compared to sample with maximal change in sum of quartiles.
Marker
CD
(N=207)
UC
(N=46)
Absolute changes in levels, median (EU (P25, P75))
gASCA 10.7 (4.1, 25.1) 2.8 (1.2, 9.6)
ACCA 14.4 (7.1, 25.8) 9.1 (3.3, 17.0)
AMCA 23.5 (8.8, 41.8) 11.8 (7.9, 21.9)
ALCA 8.5 (3.0, 16.6) 4.5 (1.8, 6.8)
Anti-L 21.5 (9.3, 41.1) 8.9 (5.3, 14.9)
Anti-C 8.0 (3.6, 16.8) 6.3 (3.3, 14.7)
Sum of quartiles 2.0 (1.0, 3.0) 1.0 (1.0, 3.0)
Absolute % changes from baseline (Median (P25, P75))
gASCA 19.0 (6.1, 33.1) 17.7 (6.8, 35.3)
ACCA 26.7 (14.8, 45.5) 19.5 (7.1, 37.0)
AMCA 31.6 (13.7, 50.1) 21.2 (15.1, 39.0)
ALCA 21.8 (8.5, 39.8) 17.0 (7.7, 31.7)
Anti-L 26.7 (12.0, 57.2) 18.3 (12.3, 29.4)
Anti-C 24.5 (11.3, 39.2) 27.6 (13.8, 39.3)
Sum of quartiles 11.1 (5.6, 23.1) 13.8 (7.1, 25.0)
gASCA: anti-Saccharomyces cerevisiae antibodies, ACCA: anti-chitobioside carbohydrate IgA antibodies, ALCA: anti-laminaribioside carbohydrate IgG antibodies, AMCA:
anti-mannobioside carbohydrate IgG antibodies, Anti-L: anti-laminarin carbohydrate antibody, Anti-C: anti-chitin carbohydrate antibody.
CD: Crohn’s disease; UC: Ulcerative colitis; EU: ELISA units; P25, P75: 25th and 75th percentiles.
doi:10.1371/journal.pone.0018172.t002
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information is critical for identifying the subgroup of patients
prone to more pronounced changes in their antibody levels during
the disease course. As the absolute antibody levels and status in
UC patients were highly stable over time we continued our
analysis with the CD cohort only. At time of first sample
procurement neither disease activity nor an elevated CRP were
linked to increased or decreased QSS or levels or status of single
markers.
We first tested the average fluctuation per individual patient using
all samples over time. For this purpose a Z-score was calculated for
each visit, averaged and associated with the above clinical
phenotypes or NOD genotypes (Tables S2 & S3). We corrected
for follow-up time and used a level of significance of p,0.01 to
account for multiple testing. No phenotype or NOD2 genotype
was associated with a higher magnitude of average fluctuations in
the marker levels. The maximal difference in Z-score between the
groups was 0.06 SD and cannot be considered clinically relevant.
To identify factors associated with maximal level fluctuations we
divided our CD patients in two different groups based on the
magnitude of maximal level changes in individual patients over
time: ‘‘Non-level changers’’ (stable QSS over time, remaining
within 0.5 standard deviations (SD) of the QSS in the initial
sample) and ‘‘Any level changers’’ (increase or decrease .0.5 SD
in QSS at any time during follow-up). These two groups were
analyzed for association with certain clinical disease phenotypes
and NOD2 genotypes (Table S4). To control for multiple testing
we used a significance level of p,0.01 and the results were
adjusted for follow-up time. We did not find any association
between the magnitude of maximal level fluctuation in our cohort
and any of the pheno- or NOD2 genotypes. We performed this
analysis with considering only CD-patients with a minimal
observation period of 12 months. Also here no association of
pheno- or genotypes with fluctuations was found (data not shown).
The antibody levels in the first sample did not predict the degree
of fluctuation of the markers at later time points in the disease
course as revealed by a logistic regression analysis (data not
shown). In other words the same degree of maximal level changes
occurred in subjects during follow-up that had high, middle or low
levels in the first sample. We additionally separated our cohort into
two groups according to changes in marker status: ‘‘Non-status
changers’’ (patients that did not change the number of positive
markers during follow-up) and ‘‘Status changers’’ (patients that
became positive or negative for one or more additional markers
during follow-up). The distribution of subjects can be found in
Table S5. We also assessed the groups for association with certain
clinical disease phenotypes and NOD2 genotypes (Table S6). We
accounted for multiple testing by using a significance level of
p,0.01 and adjusted for follow-up time. No association of pheno-
or genoptypes with fluctuations was found, when considering the
whole cohort but also when separately analyzing only CD patients
with a minimum follow-up of 12 months (data not shown).
In summary, despite considering a broad range of clinical
phenotypes and NOD2 genotypes no associations with average or
maximal changes in marker levels and status over time could be
found.
III) Level changes in individual patients over time – a
longitudinal analysis
Even though a certain clinical phenotype or NOD2 genotype
was not associated with stronger fluctuations per se, it is well likely
that changes in CD behavior or treatment can lead to changes in
the levels of the antibody markers over time. We therefore
longitudinally analyzed our CD cohort for potential level changes
inflicted by clinical situations, namely the first occurrence of
complicated CD-behavior, the first occurrence of CD-related
surgery, the use of immunosuppressive medication or the onset of
active disease. For this purpose repeated measures analysis was
done using an unstructured covariance matrix to model within-
subject correlation. The occurrence of first time complicated CD-
behavior, first time CD-related surgery, active disease or the start
of immunosuppressive medication did not influence the overall
immune response or the levels of the individual markers. Pre-event
antibody levels were not significantly different to post-event levels
taking into consideration the above parameters (Table 3 and
Figure 2 for the QSS; Table S7 for the single markers). When
looking at the use of corticosteroids separately we found a trend
towards a decrease in the QSS (data not shown). Interestingly,
overall the QSS mildly increased over time from diagnosis
(0.13 points each year), which was due to a level increase in the
IgA marker ACCA with a trend to increased levels for Anti-L and
Anti-C (Table 3). This indicates a good model fit as this is a
known phenomenon for antibodies of the IgA class.
IV) Clinical situations over time – a longitudinal analysis
The most important factor for the performance of the marker
panel is, if the accuracy in clinical situations remains unchanged
over time. We therefore tested, if the observed fluctuations in
marker levels and status alter the capability of the glycan marker
panel to differentiate between CD versus UC and their association
with CD phenotypes. We used serum of the CD patients where at
least four different samples were available during follow-up
(n=75). The expression of the glycan markers, the clinical
phenotype and the overall immune response in this subpopulation
was comparable to the total CD cohort (n=207), indicating that
no selection bias was present.
We assessed changes in the ability of the markers to differentiate
CD versus UC (Table 4). We did not observe any significant
changes in discriminatory capacity of the markers over time. We
next investigated potential changes in association with CD
phenotypes. 87.7% of the CD patients with at least four available
samples already had a complication before sample procurement at
first sample procurement, a proportion that increased to 90.8%
(2
nd sample), and 93.3% (3
rd and 4
th sample) during follow-up.
85% of the CD patients already underwent surgery once at time of
first sample, which increased during follow-up to 90% for the
other three time points. Also here an overall stable association
pattern between the markers and clinical phenotypes was found.
Independent of the time of sample procurement over the follow-up
period the overall immune response, as depicted by the sum of
Table 3. Longitudinal analysis of level changes inflicted by
clinical situations.
Sum of quartiles
Factor
Parameter
Estimate
(SE) p-value
Months since diagnosis 0.011 (0.003) 0.002
Change in disease activity 20.347 (0.443) 0.43
First occurrence of complicated CD behavior 0.021 (0.408) 0.96
First occurrence of CD-related surgery 20.654 (0.999) 0.51
Use of immunosuppressants 0.410 (0.871) 0.64
SE: Standard error; CD: Crohn’s disease.
doi:10.1371/journal.pone.0018172.t003
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associated with ileal involvement, complicated CD behavior or
CD-related surgery (Table 5; Table S8 for all single markers).
Discussion
There is a growing interest in the use of anti-glycan antibodies
as markers for differentiation and stratification of CD. Previous
reports, including ours [7,8,9,10,11,13], suggest a potential use of
these markers for discrimination between CD and UC as well as
prediction of complicated CD behavior and CD-related surgery.
Most information, however, is derived from cross-sectional studies
[7,8,9,11,13], which should be interpreted with caution, because
crucial information is missing about the stability of marker levels
and status over time in individual patients, an open question we
specifically addressed in our investigation.
We detected marked changes in the overall immune response
(QSS) and levels of individual markers in a subgroup of CD
subjects over time. The marker status (positive versus negative)
remained widely stable. None of our tested clinical phenotypes or
NOD2 genotypes was associated with stronger average or maximal
changes in marker levels. In a longitudinal analysis with individual
patients over time neither changes in disease activity, CD behavior
or surgery, nor the intake of immunosuppressive medication led to
changes in the QSS. The ability of the panel to discriminate CD
versus UC or its association with CD location, behavior or surgery
remained stable during the follow-up time. In UC neither
significant absolute level nor status changes were observed.
Incomplete and limited information is available on fluctuations
in level and status of serum antibodies directed against microbial
components and associated with CD over time. Most data derived
from cross-sectional single point studies are controversial: In 32% of
apparently healthy recruits of the Israeli Defence Forces, who were
later diagnosed as having CD, levels of ASCA increased closer to
the date of diagnosis [27]. Once diagnosis of CD was established
disease duration did not seem to influence serological responses in
several reports, investigating ASCA, OmpC, Anti-I2 and CBir1
[19,21]. In contrast to this, others found significant higher
antibody responses against ASCA, AMCA, ACCA and OmpC
associated with increased disease duration [7,9]. Oshitani et al.
demonstrated lower ASCA titers in CD patients taking mesalazine
compared to CD patients not taking mesalazine [17]. In contrary,
Ruemmele et al. reported no difference in ASCA positivity with
steroid and mesalazine treatment in a pediatric population. A
decline in ASCA levels towards normal values had been observed
post-surgically in CD [16]. Changes in disease activity did not
seem to influence marker levels [9,11].
The information derived from longitudinal studies in individual
patients over time is even scarcer and meaningful conclusions are
difficult to make due to limited follow-up times or low patient
numbers. Dotan et al. followed the serum levels of the glycan-
markers anti-alpha-Rha, anti-alpha-GlcNAc and anti-cellotriose
Figure 2. Change in the serum immune response in relation to clinical events. Change in antibody levels (quartile sum score) with (A) the
first occurrence of Crohn’s disease (CD)-related surgery (n=17), (B) complications (fistulae or strictures; n=16), (C) new intake of immunsuppressive
medication (depicted is a random set of 25 patients out of total n=152) or (D) onset of active disease (depicted is a random set of 25 patients out of
total n=124). Numbers relate to months before or after the event for A & B and months between the two samples for C & D (interquartile range
(IQR)).
doi:10.1371/journal.pone.0018172.g002
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weeks and found widely stable levels over time [28]. In a pediatric
cohort (n=61) with a mean follow-up time of 4.9 years and up to
seven measurements during the CD course only 21 to 29.5% of
the subjects changed ASCA status over time. Even though
individual patients showed marked changes in titers the average
levels across the total population showed little variability during
follow-up [23].
Disease activity or relapse does not appear to influence marker
levels in longitudinal studies [23,29]. ASCA was stable over time in
relation to changes in CDAI, monitoring 26 CD patients before
and after infliximab therapy for a median interval of 6.1 months
[19]. Among patients who achieved complete remission through
treatment with infliximab as evidenced by mucosal changes and
healing, stability in anti-CBir1 expression was seen (n=14) [21].
ASCA titers in CD patients taking mesalazine versus placebo for
prophylaxis of postoperative relapse (n=38) remained stable over
time [20]. However, ASCA levels decreased after two weeks of
corticosteroid treatment (n=25, follow-up 9 weeks) [20]. A
decrease in ASCA levels after intestinal surgery with a later rise
to preoperative levels within a few months was noted (n=60) [22].
In contrast no significant changes in serological responses toward
ASCA, Anti-I2 and Omp-C after small bowel surgery (n=61 and
26) with or without fecal diversion (n=14) was found [14,23,24].
Our study describes the dynamic change of anti-glycan
antibodies in the to date largest cohort of CD patients with
multiple samples collected during the disease course and
scrutinizes detailed clinical information for each time point of
sample procurement. Comparable studies but of smaller size have
so far only been reported for ASCA [14,22,23].
We established that during the disease course significant
fluctuations in marker levels occur in a subgroup of CD patients.
The marker status, however, remained strikingly stable. Consid-
ering all markers a change in status occurred in only 3.3% of the
visits per antibody. In an attempt to identify specific clinical
phenotypes or genotypes that are associated with stronger level or
status changes we included a wide range of phenotypes into our
statistical analysis. Interestingly none of the clinical phenotypes
was associated with level or status changes in antibodies over time.
The immune response tended to decrease with intake of
corticosteroids. This is in concordance with a previous report
[20], but the effect was not noted when all immunosuppressive
medications (including corticosteroids, azathioprine and metho-
trexate) were considered in the model. None of our patients
received infliximab during the observation period.
The fact that our association analysis for disease phenotypes
confirms the previously reported results from our larger cohort
[11] underlines the appropriate power of our study to detect
potential changes in marker levels and status, if they were present.
In addition our longitudinal analysis detected a mild increase in
the levels of the glycan IgA markers over time indicating a good
model fit, because a rise in the serum titers of IgA antibodies over
time is a known physiologic phenomenon. We see two possible
explanations for our lack of association of phenotypes/phenotype
changes with fluctuations: A clinical phenotype or genotype not
considered in our model might lead to the observed changes.
Alternatively our observation may reflect the natural fluctuation of
the markers/immune response over time. This is supported by the
finding of comparable results in relative changes of the marker levels
(Table 2) with essentially identical Z-scores between CD and UC.
UC is not associated with higher levels of anti glycan antibodies
and, therefore, the absolute fluctuations are minute and not
clinically relevant. The onset of level changes inflicted by clinical
situation might be delayed, e.g. an increase in serologic glycan
marker levels might lag behind an increase in disease activity and
therefore would not be detected in our longitudinal analysis.
Determination of glycan markers in clinical practice may allow
the differentiation between UC and CD, which could impact the
type of therapy chosen for the respective disease. In addition, the
ability to predict the progression from non-complicated to
complicated disease and/or surgery with serum markers may
classify patients into at-risk populations and influence the
therapeutic management of patients with the goal of preventing
the development of complications. One prerequisite for routine
use is the stability of markers over time. The most important
finding of our study is that despite the observed changes in the
QSS the potency of the markers in clinical situations, namely
discrimination between UC versus CD and association with CD
phenotypes remained stable over time. Given the marker status
stability over time in our study, association of marker positivity
with CD and certain disease phenotypes are likely to be suitable as
Table 4. Validity of markers for differentiation of CD versus
UC over time in individual patients.
Antibody Sensitivity (%) Specificity (%) PPV (%) NPV (%)
1st Sample
gASCA 69.3 91.3 92.9 64.6
ACCA 24 91.3 81.8 42.4
AMCA 29.3 93.5 88 44.8
ALCA 34.7 95.7 92.9 47.3
Anti-L 28.4 93 87.5 43
Anti-C 36.5 88.4 84.4 44.7
2nd Sample
gASCA 69.3 91.3 92.9 64.6
ACCA 17.3 91.3 76.5 40.4
AMCA 24 93.5 85.7 43
ALCA 29.3 95.7 91.7 45.4
Anti-L 28.4 93 87.5 43
Anti-C 25.7 88.4 79.2 40.9
3rd Sample
gASCA 69.3 91.3 92.9 64.6
ACCA 18.7 91.3 77.8 40.8
AMCA 21.3 93.5 84.2 42.2
ALCA 33.3 95.7 92.6 46.8
Anti-L 33.3 93 89.3 44.4
Anti-C 20 88.4 75 38.8
4th Sample
gASCA 70.7 91.3 93 65.6
ACCA 10.7 91.3 66.7 38.5
AMCA 17.3 93.5 81.3 41
ALCA 30.7 95.7 92 45.8
Anti-L 31.1 93 88.5 44
Anti-C 31.1 88.4 82.1 42.7
Includes 75 CD subjects with at least four samples per individual patient versus
all 46 UC subjects.
PPV: positive predictive value, NPV: negative predictive value.
gASCA: anti-Saccharomyces cerevisiae antibodies, ACCA: anti-chitobioside
carbohydrate IgA antibodies, ALCA: anti-laminaribioside carbohydrate IgG
antibodies, AMCA: anti-mannobioside carbohydrate IgG antibodies, Anti-L: anti-
laminarin carbohydrate antibody, Anti-C: anti-chitin carbohydrate antibody.
doi:10.1371/journal.pone.0018172.t004
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independent of the time of sample procurement. Therefore, serial
measurements of antibodies may not provide additional informa-
tion for the evaluation of CD when considering the status of the
markers. On the other hand the marked fluctuations in the QSS in
a subgroup of CD patients suggests caution when using the overall
immune response for the aforementioned clinical situations,
namely diagnosis, differential diagnosis and disease stratification.
The strength of our study is its originality by being the first study
investigating fluctuations in anti-glycan antibodies, the prospective
follow-up design, blinded data abstraction, availability of up to 11
samples per patient and a longitudinal analysis paired with detailed
clinical information. However, certain limitations apply: One has to
keep in mind that our cohort is from a single university hospital,
introducing possible referral bias. The first serum sample per patient
wasnotinallcasestakenclosetodiagnosis,whichwecorrected forin
our statistical models. The follow-up samples were taken at arbitrary
visits to our hospital and not in a fixed relation to certain events such
as complications or surgery, information that was retrospectively
added. Using thismethod,patients with a moreseverediseasecourse
could be selected out, as only they have to come to a referral center
for multiple treatments. The length of time in which immunosup-
pressive medication was taken by the patients before sample
procurement is unknown to the authors, which is a limitation for
our longitudinal model. We are aware of the potential presence of a
subclinicalcomplicationatthe time of sampleprocurement.Onehas
to consider that this study does not aim at prediction of complicated
CD courseswith serology, but ratherevaluatesthe fluctuations of the
glycan markers longitudinally to assess, if and how already published
cross sectional studies can be used for disease prediction. Even
though this is the largest study of its kind ever reported, the overall
number of patients is limited. A larger cohort would enable a more
detailed analysis with respect to determinants of level changes.
In summary, our study indicates that anti-glycan antibody levels
are changing in patients with CD whereas the status of the markers
is stable over time. The observed fluctuations might be due to not
yet identified clinical factors or genotypes or could represent
natural changes in levels over time. Considering the follow-up time
of our study we cannot recommend serial measurements, when
considering the marker status and claim to use the overall immune
response (QSS) with caution for disease stratification, due to strong
fluctuations in a subgroup of CD subjects.
Supporting Information
Figure S1 Changes in the level of single markers over
time. Profile plots for changes in the levels of single markers in
individual Crohn’s disease (CD) patients over time. The broken
line represents the cut-off value for each individual marker. The
red lines indicate patients starting above the cut-off value and the
green lines indicate subjects starting below the cut-off values.
Depicted is a random set of 50 subjects per graph. gASCA: anti-
Saccharomyces cerevisiae antibodies, ACCA: anti-chitobioside carbo-
hydrate IgA antibodies, ALCA: anti-laminaribioside carbohydrate
IgG antibodies, AMCA: anti-mannobioside carbohydrate IgG
antibodies, Anti-L: anti-laminarin carbohydrate antibody, Anti-C:
anti-chitin carbohydrate antibody.
(TIF)
Figure S2 Maximal changes in levels of single markers
in Crohn’s disease. Scatter plot comparing the level of the first
sample and the sample with the maximal changes in quartile sum
score during follow-up for each individual marker in Crohn’s
disease (CD) patients. One dot represents one patient. gASCA:
anti-Saccharomyces cerevisiae antibodies, ACCA: anti-chitobioside
carbohydrate IgA antibodies, ALCA: anti-laminaribioside carbo-
hydrate IgG antibodies, AMCA: anti-mannobioside carbohydrate
Table 5. Validity of markers for association with disease phenotypes over time in individual patients.
Ileum
Involvement
No Ileum
Involvement Complication
No
Complication Surgery No Surgery
Factor (N=67) (N=8) p-value (N=65) (N=10) p-value (N=60) (N=15)
p-
value
1st Sample
Sum of quartiles 16.0 (13.5, 19.5) 10.0 (8.0, 14.0) ,0.001 17.0 (13.0, 20.0) 10.0 (8.0, 14.0) ,0.001 17.5 (14.0, 21.0) 14.0 (10.0, 16.0) 0.003
Number of positive
markers
2.0 (1.0, 3.0) 0.0 (0.0, 1.0) ,0.001 2.0 (1.0, 4.0) 0.0 (0.0, 1.0) ,0.001 2.0 (1.0, 4.0) 1.0 (0.0, 2.0) 0.002
2nd Sample
Sum of quartiles 15.5 (12.0, 19.0) 10.0 (8.0, 14.0) ,0.001 16.0 (12.0, 19.0) 10.0 (8.0, 13.0) ,0.001 16.5 (13.0, 19.5) 12.0 (12.0, 15.0) 0.004
Number of positive
markers
2.0 (1.0, 3.0) 0.0 (0.0, 1.0) ,0.001 2.0 (1.0, 3.0) 0.0 (0.0, 1.0) ,0.001 2.0 (1.0, 3.0) 1.0 (0.0, 2.0) 0.003
3rd Sample
Sum of quartiles 15.0 (12.0, 19.0) 10.0 (8.0, 14.0) ,0.001 15.0 (12.0, 19.0) 9.0 (7.0, 13.0) ,0.001 16.5 (13.0, 19.0) 11.0 (8.0, 15.0) 0.004
Number of positive
markers
2.0 (1.0, 3.0) 0.0 (0.0, 1.0) ,0.001 2.0 (1.0, 3.0) 0.0 (0.0, 1.0) ,0.001 2.0 (1.0, 3.0) 1.0 (0.0, 2.0) 0.006
4th Sample
Sum of quartiles 15.0 (12.0, 19.0) 10.0 (8.0, 14.0) ,0.001 15.0 (12.0, 19.0) 10.0 (8.0, 14.0) ,0.001 15.0 (13.0, 20.0) 13.0 (10.0, 16.0) 0.02
Number of positive
markers
2.0 (1.0, 3.0) 0.0 (0.0, 1.0) ,0.001 2.0 (1.0, 3.0) 0.0 (0.0, 1.0) ,0.001 2.0 (1.0, 3.0) 1.0 (0.0, 2.0) 0.025
Includes 75 CD subjects with at least four samples per individual patient.
Sum of quartiles: Values presented are median (25th percentile, 75th percentile) and P-values correspond to Wilcoxon rank sum tests.
Antibody positivity: Values presented are N (%) and P-values correspond to Fisher’s Exact test (F) and Pearson’s chi-square tests otherwise.
Complication: fistula or stenosis.
doi:10.1371/journal.pone.0018172.t005
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Anti-C: anti-chitin carbohydrate antibody.
(TIF)
Figure S3 Maximal changes in levels of single markers
in Ulcerative colitis. Scatter plot comparing the level of the first
sample and the sample with the maximal changes in quartile sum
score during follow-up for each individual marker in Ulcerative
colitis (UC) subjects. One dot represents one patient. gASCA: anti-
Saccharomyces cerevisiae antibodies, ACCA: anti-chitobioside carbo-
hydrate IgA antibodies, ALCA: anti-laminaribioside carbohydrate
IgG antibodies, AMCA: anti-mannobioside carbohydrate IgG
antibodies, Anti-L: anti-laminarin carbohydrate antibody, Anti-C:
anti-chitin carbohydrate antibody.
(TIF)
Table S1 Average of absolute standard deviations around the
mean (Z-score).
(TIFF)
Table S2 Average of absolute standard deviations around the
mean (Z-score) and association with disease pheno- and NOD2
genotypes.
(TIFF)
Table S3 Correlation coefficients of the Z-score with disease
parameters.
(TIFF)
Table S4 Association of clinical phenotypes and genotypes with
maximal level changes.
(TIFF)
Table S5 Number and distribution of CD subjects with antibody
status changes.
(TIFF)
Table S6 Assosiation of clinical phenotypes and genotypes with
status changes.
(TIFF)
Table S7 Longitudinal analysis of level changes inflicted by
clinical situations.
(TIFF)
Table S8 Validity of markers for association with disease
phenotypes over time in individual patients.
(TIFF)
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